201 related articles for article (PubMed ID: 29178442)
1. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.
Vishwanathan K; Dickinson PA; Bui K; Cassier PA; Greystoke A; Lisbon E; Moreno V; So K; Thomas K; Weilert D; Yap TA; Plummer R
J Clin Pharmacol; 2018 Apr; 58(4):474-484. PubMed ID: 29178442
[TBL] [Abstract][Full Text] [Related]
2. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
Vishwanathan K; Dickinson PA; So K; Thomas K; Chen YM; De Castro Carpeño J; Dingemans AC; Kim HR; Kim JH; Krebs MG; Chih-Hsin Yang J; Bui K; Weilert D; Harvey RD
Br J Clin Pharmacol; 2018 Jun; 84(6):1156-1169. PubMed ID: 29381826
[TBL] [Abstract][Full Text] [Related]
3. Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies.
Planchard D; Brown KH; Kim DW; Kim SW; Ohe Y; Felip E; Leese P; Cantarini M; Vishwanathan K; Jänne PA; Ranson M; Dickinson PA
Cancer Chemother Pharmacol; 2016 Apr; 77(4):767-76. PubMed ID: 26902828
[TBL] [Abstract][Full Text] [Related]
4. Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Calvo E; Lee JS; Kim SW; Moreno V; deCastro Carpeno J; Weilert D; Laus G; Mann H; Vishwanathan K
J Clin Pharmacol; 2019 Aug; 59(8):1099-1109. PubMed ID: 30875094
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study.
Zhao H; Cao J; Chang J; Zhang Z; Yang L; Wang J; Cantarini M; Zhang L
J Clin Pharmacol; 2018 Apr; 58(4):504-513. PubMed ID: 29239002
[TBL] [Abstract][Full Text] [Related]
6. Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects.
Lindsay J; Mudge S; Thompson GR
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297369
[TBL] [Abstract][Full Text] [Related]
7. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
Quinn DI; Nemunaitis J; Fuloria J; Britten CD; Gabrail N; Yee L; Acharya M; Chan K; Cohen N; Dudov A
Clin Pharmacokinet; 2009; 48(3):199-209. PubMed ID: 19385713
[TBL] [Abstract][Full Text] [Related]
8. An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor.
Cheng Y; Liu L; Xue Y; Zhou S; Li Y
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):579-592. PubMed ID: 35657581
[TBL] [Abstract][Full Text] [Related]
9. Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats.
Yasumuro O; Uchida S; Kashiwagura Y; Suzuki A; Tanaka S; Inui N; Watanabe H; Namiki N
Xenobiotica; 2018 Nov; 48(11):1106-1112. PubMed ID: 29057719
[TBL] [Abstract][Full Text] [Related]
10. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
[TBL] [Abstract][Full Text] [Related]
11. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib.
Egorin MJ; Shah DD; Christner SM; Yerk MA; Komazec KA; Appleman LR; Redner RL; Miller BM; Beumer JH
Br J Clin Pharmacol; 2009 Sep; 68(3):370-4. PubMed ID: 19740393
[TBL] [Abstract][Full Text] [Related]
12. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
Goss G; Tsai CM; Shepherd FA; Bazhenova L; Lee JS; Chang GC; Crino L; Satouchi M; Chu Q; Hida T; Han JY; Juan O; Dunphy F; Nishio M; Kang JH; Majem M; Mann H; Cantarini M; Ghiorghiu S; Mitsudomi T
Lancet Oncol; 2016 Dec; 17(12):1643-1652. PubMed ID: 27751847
[TBL] [Abstract][Full Text] [Related]
13. The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects.
Anderson K; Zheng H; Kotecha M; Cuvin J; Scott B; Sharma S; Qin AR; Namour F; Xin Y
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):585-594. PubMed ID: 30768860
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor.
Dickinson PA; Cantarini MV; Collier J; Frewer P; Martin S; Pickup K; Ballard P
Drug Metab Dispos; 2016 Aug; 44(8):1201-12. PubMed ID: 27226351
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment.
Vishwanathan K; Sanchez-Simon I; Keam B; Penel N; de Miguel-Luken M; Weilert D; Mills A; Marotti M; Johnson M; Ravaud A
Pharmacol Res Perspect; 2020 Aug; 8(4):e00613. PubMed ID: 32567817
[TBL] [Abstract][Full Text] [Related]
16. Effect of an Antacid (Aluminum Hydroxide/Magnesium Hydroxide/Simethicone) or a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Adult Subjects.
Patel G; Gupta VK; Gasink L; Bajraktari F; Lei Y; Jain A; Srivastava P; Talley AK
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0149522. PubMed ID: 36943038
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers.
Li L; Xiang YX; Yang GP; Zhang XF; Yang XY; Yang S; Huang J
Invest New Drugs; 2021 Jun; 39(3):796-802. PubMed ID: 33420642
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants.
Xu H; O'Gorman MT; Nepal S; James LP; Ginman K; Pithavala YK
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1395-1404. PubMed ID: 34288547
[TBL] [Abstract][Full Text] [Related]
19. Effect of food on the bioavailability of palbociclib.
Ruiz-Garcia A; Plotka A; O'Gorman M; Wang DD
Cancer Chemother Pharmacol; 2017 Mar; 79(3):527-533. PubMed ID: 28204912
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer.
Brown K; Comisar C; Witjes H; Maringwa J; de Greef R; Vishwanathan K; Cantarini M; Cox E
Br J Clin Pharmacol; 2017 Jun; 83(6):1216-1226. PubMed ID: 28009438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
